methocarbamol 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
	1747	532-03-6

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: methocarbamol glycerylguaiacolate carbamate guaiacol glyceryl ether carbamate guaiphenesin carbamate guaiamar carbamate	A centrally acting muscle relaxant whose mode of action has not been established. It is used as an adjunct in the symptomatic treatment of musculoskeletal conditions associated with painful muscle spasm. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1206) Molecular weight: 241.24 Formula: C11H15NO5 CLOGP: 0.15 LIPINSKI: 0 HAC: 6 HDO: 2 TPSA: 91.01 ALOGS: -1.76 ROTB: 7 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

methocarbamol
glycerylguaiacolate carbamate
guaiacol glyceryl ether carbamate
guaiphenesin carbamate
guaiamar carbamate

A centrally acting muscle relaxant whose mode of action has not been established. It is used as an adjunct in the symptomatic treatment of musculoskeletal conditions associated with painful muscle spasm. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1206)

Molecular weight: 241.24
Formula: C11H15NO5
CLOGP: 0.15
LIPINSKI: 0
HAC: 6
HDO: 2
TPSA: 91.01
ALOGS: -1.76
ROTB: 7

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

Dose	Unit	Route
3	g	O
3	g	P

ADMET properties:

None

Approvals:

Date	Agency	Company	Orphan
July 16, 1957	FDA	AUXILIUM PHARMS LLC

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Completed suicide	77.23	12.56	158	18485	131731	50454750
Necrosis ischaemic	64.68	12.56	20	18623	779	50585702
Pneumonia streptococcal	54.24	12.56	21	18622	1610	50584871
Beta haemolytic streptococcal infection	48.48	12.56	20	18623	1810	50584671
Acquired haemophilia	46.31	12.56	16	18627	887	50585594
Gallbladder polyp	41.78	12.56	14	18629	707	50585774
Multiple drug therapy	37.62	12.56	17	18626	1920	50584561
Maternal exposure during pregnancy	37.03	12.56	7	18636	159771	50426710
Treatment failure	36.61	12.56	4	18639	137633	50448848
Diabetes mellitus inadequate control	35.19	12.56	33	18610	13112	50573369
Muscle spasms	33.42	12.56	112	18531	125441	50461040
Systemic lupus erythematosus	32.93	12.56	6	18637	140616	50445865
Drug intolerance	32.91	12.56	20	18623	219084	50367397
Infusion related reaction	32.43	12.56	11	18632	169546	50416935
Migraine	29.43	12.56	77	18566	75203	50511278
Drug hypersensitivity	29.28	12.56	175	18468	250835	50335646
Spinal operation	27.70	12.56	21	18622	6239	50580242
Glossodynia	26.90	12.56	5	18638	115564	50470917
Anxiety	26.90	12.56	133	18510	177473	50409008
Amnesia	26.32	12.56	52	18591	42208	50544273
Depression	25.85	12.56	125	18518	165298	50421183
Exposure via skin contact	25.02	12.56	7	18636	191	50586290
Fall	24.73	12.56	209	18434	334723	50251758
Surgery	22.33	12.56	40	18603	30165	50556316
Intervertebral disc protrusion	21.90	12.56	32	18611	20361	50566120
Off label use	20.83	12.56	97	18546	474329	50112152
Exercise tolerance decreased	20.80	12.56	16	18627	4858	50581623
Blood pressure inadequately controlled	20.06	12.56	15	18628	4365	50582116
Withdrawal syndrome	19.47	12.56	28	18615	17562	50568919
Pre-existing condition improved	19.35	12.56	18	18625	7079	50579402
Road traffic accident	18.97	12.56	33	18610	24319	50562162
Neutropenia	18.94	12.56	16	18627	147949	50438532
Respiratory arrest	18.77	12.56	37	18606	29972	50556509
Back disorder	18.71	12.56	20	18623	9285	50577196
Joint swelling	18.66	12.56	39	18604	245247	50341234
Fibromyalgia	18.60	12.56	47	18596	44931	50541550
Lower respiratory tract infection	18.50	12.56	6	18637	95195	50491286
Back pain	18.21	12.56	141	18502	219889	50366592
Analgesic drug level increased	18.17	12.56	10	18633	1721	50584760
Multiple sclerosis relapse	17.87	12.56	45	18598	42919	50543562
Hypertension	17.84	12.56	136	18507	211067	50375414
Suspected suicide	17.40	12.56	15	18628	5342	50581139
Exposure during pregnancy	16.86	12.56	12	18631	121003	50465478
Wound	16.81	12.56	9	18634	105785	50480696
Cardiac failure	16.24	12.56	4	18639	76036	50510445
Alopecia	16.20	12.56	42	18601	245005	50341476
Febrile neutropenia	15.97	12.56	8	18635	97659	50488822
Thyroiditis chronic	15.90	12.56	3	18640	12	50586469
Loss of consciousness	15.67	12.56	78	18565	104275	50482206
Product dose omission issue	15.31	12.56	118	18525	183720	50402761
Therapy interrupted	15.29	12.56	27	18616	20125	50566356
Attention deficit hyperactivity disorder	15.03	12.56	10	18633	2419	50584062
Therapy cessation	14.99	12.56	31	18612	25980	50560501
Oesophagitis	14.37	12.56	21	18622	13362	50573119
Memory impairment	13.87	12.56	62	18581	79298	50507183
Somnolence	13.76	12.56	101	18542	154884	50431597
Synovial cyst	13.75	12.56	16	18627	8150	50578331
Neck pain	13.51	12.56	49	18594	57018	50529463
Cardio-respiratory arrest	13.38	12.56	47	18596	53845	50532636
Pharyngeal swelling	13.26	12.56	12	18631	4554	50581927
Malignant neoplasm of spinal cord	13.04	12.56	3	18640	36	50586445
Feeling abnormal	13.04	12.56	85	18558	125407	50461074
Psoriasis	12.89	12.56	55	18588	68945	50517536
Illness	12.70	12.56	28	18615	24512	50561969
Suicidal ideation	12.64	12.56	47	18596	55338	50531143

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Drug dependence	85.31	14.87	59	7894	20922	29545652
Product prescribing error	55.90	14.87	43	7910	17933	29548641
Respiratory depression	52.54	14.87	37	7916	13486	29553088
Victim of child abuse	39.85	14.87	13	7940	832	29565742
Child abuse	35.85	14.87	9	7944	222	29566352
Depression	30.15	14.87	69	7884	85078	29481496
Phonophobia	28.03	14.87	7	7946	169	29566405
Back disorder	22.40	14.87	16	7937	5957	29560617
Epidural lipomatosis	22.07	14.87	8	7945	703	29565871
Memory impairment	20.67	14.87	36	7917	36434	29530140
Intentional product misuse	19.36	14.87	34	7919	34627	29531947
Anxiety	18.79	14.87	58	7895	85307	29481267
Serum procollagen type III N-terminal propeptide increased	18.14	14.87	4	7949	55	29566519
Spinal operation	18.00	14.87	10	7943	2404	29564170
Back pain	17.64	14.87	64	7889	102220	29464354
Juvenile idiopathic arthritis	16.86	14.87	8	7945	1386	29565188
Post-traumatic neck syndrome	15.77	14.87	4	7949	103	29566471

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Completed suicide	65.68	12.42	189	20514	224225	64253804
Necrosis ischaemic	63.31	12.42	20	20683	963	64477066
Drug dependence	57.73	12.42	62	20641	33250	64444779
Beta haemolytic streptococcal infection	50.49	12.42	20	20683	1874	64476155
Pneumonia streptococcal	46.09	12.42	20	20683	2358	64475671
Gallbladder polyp	40.44	12.42	14	20689	898	64477131
Acquired haemophilia	39.35	12.42	16	20687	1604	64476425
Victim of child abuse	37.20	12.42	13	20690	858	64477171
Anxiety	36.44	12.42	145	20558	202504	64275525
Product prescribing error	35.63	12.42	50	20653	35219	64442810
Depression	35.27	12.42	134	20569	183157	64294872
Child abuse	34.70	12.42	9	20694	211	64477818
Respiratory depression	31.08	12.42	38	20665	23405	64454624
Back disorder	29.56	12.42	25	20678	9965	64468064
Respiratory arrest	28.98	12.42	57	20646	52928	64425101
Spinal operation	28.35	12.42	20	20683	6113	64471916
Multiple drug therapy	28.21	12.42	14	20689	2240	64475789
Neutropenia	27.45	12.42	22	20681	239602	64238427
Exposure via skin contact	27.12	12.42	7	20696	161	64477868
Migraine	26.82	12.42	61	20642	62616	64415413
Drug hypersensitivity	25.79	12.42	147	20556	237668	64240361
Fall	24.91	12.42	223	20480	416603	64061426
Drug intolerance	24.51	12.42	15	20688	187977	64290052
Contraindicated product administered	24.30	12.42	3	20700	107826	64370203
Back pain	24.15	12.42	150	20553	250021	64228008
Infusion related reaction	23.05	12.42	12	20691	164455	64313574
Muscle spasms	23.03	12.42	98	20605	140925	64337104
Memory impairment	22.94	12.42	70	20633	85612	64392417
Cardiac failure	22.90	12.42	7	20696	132366	64345663
Diabetes mellitus inadequate control	22.69	12.42	31	20672	21290	64456739
Drug abuser	22.45	12.42	17	20686	5791	64472238
Pancytopenia	22.35	12.42	9	20694	143300	64334729
Back injury	22.11	12.42	19	20684	7738	64470291
Thrombocytopenia	21.58	12.42	24	20679	223777	64254252
Intentional product misuse	21.20	12.42	61	20642	72234	64405795
Road traffic accident	20.48	12.42	36	20667	30709	64447320
Surgery	20.05	12.42	34	20669	28179	64449850
Contusion	20.02	12.42	81	20622	113884	64364145
Phonophobia	19.87	12.42	7	20696	473	64477556
Multiple sclerosis relapse	19.83	12.42	42	20661	41093	64436936
Epidural lipomatosis	19.06	12.42	8	20695	869	64477160
Intervertebral disc degeneration	18.59	12.42	22	20681	13098	64464931
Feeling abnormal	18.19	12.42	88	20615	133514	64344515
Overdose	18.18	12.42	100	20603	159466	64318563
Pain	18.00	12.42	263	20440	553248	63924781
Serum procollagen type III N-terminal propeptide increased	17.93	12.42	4	20699	48	64477981
Loss of consciousness	17.59	12.42	94	20609	148271	64329758
Amnesia	17.44	12.42	44	20659	48225	64429804
Treatment failure	17.16	12.42	8	20695	116808	64361221
Analgesic drug level increased	16.92	12.42	10	20693	2260	64475769
Hypertension	16.65	12.42	141	20562	259120	64218909
Intervertebral disc protrusion	16.61	12.42	26	20677	20165	64457864
Off label use	16.15	12.42	128	20575	632678	63845351
Suicidal ideation	15.65	12.42	52	20651	66490	64411539
Emotional distress	15.33	12.42	35	20668	36003	64442026
Attention deficit hyperactivity disorder	15.09	12.42	10	20693	2760	64475269
Pain in extremity	15.03	12.42	156	20547	302929	64175100
Cardio-respiratory arrest	15.00	12.42	67	20636	98326	64379703
Maternal exposure during pregnancy	14.98	12.42	6	20697	95878	64382151
Blood pressure inadequately controlled	14.96	12.42	13	20690	5371	64472658
Malignant neoplasm progression	14.71	12.42	9	20694	112862	64365167
Insomnia	14.55	12.42	111	20592	197725	64280304
Oesophageal stenosis	14.33	12.42	11	20692	3823	64474206
Therapy cessation	14.32	12.42	32	20671	32457	64445572
Interstitial lung disease	13.89	12.42	7	20696	97725	64380304
Pyrexia	13.78	12.42	114	20589	558530	63919499
Systemic lupus erythematosus	13.61	12.42	4	20699	77608	64400421
Suspected suicide	13.08	12.42	15	20688	8639	64469390
Intervertebral disc displacement	13.04	12.42	5	20698	429	64477600
Drug interaction	12.94	12.42	66	20637	362017	64116012
Therapy interrupted	12.75	12.42	23	20680	20013	64458016
Pharyngeal swelling	12.66	12.42	12	20691	5547	64472482
Vision blurred	12.66	12.42	60	20643	90256	64387773
Spinal osteoarthritis	12.54	12.42	19	20684	14322	64463707
Febrile neutropenia	12.42	12.42	26	20677	187631	64290398

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	M03BA03	MUSCULO-SKELETAL SYSTEM MUSCLE RELAXANTS MUSCLE RELAXANTS, CENTRALLY ACTING AGENTS Carbamic acid esters
ATC	M03BA53	MUSCULO-SKELETAL SYSTEM MUSCLE RELAXANTS MUSCLE RELAXANTS, CENTRALLY ACTING AGENTS Carbamic acid esters
ATC	M03BA73	MUSCULO-SKELETAL SYSTEM MUSCLE RELAXANTS MUSCLE RELAXANTS, CENTRALLY ACTING AGENTS Carbamic acid esters
MeSH PA	D002491	Central Nervous System Agents
MeSH PA	D009125	Muscle Relaxants, Central
MeSH PA	D009465	Neuromuscular Agents
MeSH PA	D018373	Peripheral Nervous System Agents
CHEBI has role	CHEBI:51371	muscle relaxants
FDA PE	N0000175730	Centrally-mediated Muscle Relaxation
FDA EPC	N0000175737	Muscle Relaxant

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Spasticity	indication	221360009
Muscle Spasm with Pain	indication
Tetanus Adjunct Treatment	indication
Alcoholism	contraindication	7200002
Peptic ulcer	contraindication	13200003	DOID:750
Gastrointestinal ulcer	contraindication	40845000
Vitamin K deficiency	contraindication	52675005	DOID:11249
Nasal polyp	contraindication	52756005
Acute nephropathy	contraindication	58574008
Factor II deficiency	contraindication	73975000
Reye's syndrome	contraindication	74351001	DOID:14525
Gastrointestinal hemorrhage	contraindication	74474003
Thrombotic thrombocytopenic purpura	contraindication	78129009	DOID:10772
Gout	contraindication	90560007	DOID:13189
Kidney disease	contraindication	90708001	DOID:557
Hemophilia	contraindication	90935002
Anemia due to enzyme deficiency	contraindication	111577008
von Willebrand disorder	contraindication	128105004	DOID:12531
Seizure disorder	contraindication	128613002
Disease of liver	contraindication	235856003	DOID:409
Anemia	contraindication	271737000	DOID:2355
Pregnancy, function	contraindication	289908002
Thrombocytopenic disorder	contraindication	302215000	DOID:1588
Breastfeeding (mother)	contraindication	413712001
Acute erosive gastritis	contraindication	444926003

🐶 Veterinary Drug Use

Species	Use	Relation
Cats	Acute inflammatory and traumatic conditions of the skeletal muscles	Indication
Cats	Reducing muscular spasms	Indication
Dogs	Acute inflammatory and traumatic conditions of the skeletal muscles	Indication
Dogs	Reducing muscular spasms	Indication
Horses	Acute inflammatory and traumatic conditions of the skeletal muscles	Indication
Horses	Reducing muscular spasms	Indication

🐶 Veterinary products

Product	Applicant	Ingredients
Robaxin-V Injectable	Kinetic Technologies LLC	1
Robaxin-V Tablets	Zoetis Inc.	1

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Mechanism action	Bioact source	MoA source
Carbonic anhydrase 1	Enzyme	P00915	CAH1_HUMAN	INHIBITOR	Ki	7.60		IUPHAR	CHEMBL

External reference:

ID	Source
4017879	VUID
N0000146232	NUI
D00402	KEGG_DRUG
4017879	VANDF
C0025659	UMLSCUI
CHEBI:6832	CHEBI
CHEMBL1201117	ChEMBL_ID
DB00423	DRUGBANK_ID
D008721	MESH_DESCRIPTOR_UI
4107	PUBCHEM_CID
6829	IUPHAR_LIGAND_ID
776	INN_ID
125OD7737X	UNII
6845	RXNORM
5075	MMSL
988	MMSL
d00965	MMSL
001669	NDDF
387486000	SNOMEDCT_US
83973001	SNOMEDCT_US

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Methocarbamol	HUMAN PRESCRIPTION DRUG LABEL	1	0143-1290	TABLET	500 mg	ORAL	ANDA	21 sections
Methocarbamol	HUMAN PRESCRIPTION DRUG LABEL	1	0143-1292	TABLET	750 mg	ORAL	ANDA	21 sections
Methocarbamol	HUMAN PRESCRIPTION DRUG LABEL	1	0404-9909	INJECTION, SOLUTION	100 mg	INTRAVENOUS	ANDA	11 sections
Methocarbamol	HUMAN PRESCRIPTION DRUG LABEL	1	0404-9909	INJECTION, SOLUTION	100 mg	INTRAVENOUS	ANDA	11 sections
Methocarbamol	HUMAN PRESCRIPTION DRUG LABEL	1	0440-1740	TABLET	500 mg	ORAL	ANDA	23 sections
Methocarbamol	HUMAN PRESCRIPTION DRUG LABEL	1	0517-1825	INJECTION	100 mg	INTRAMUSCULAR	ANDA	20 sections
ROBAXIN	HUMAN PRESCRIPTION DRUG LABEL	1	0641-6103	INJECTION	100 mg	INTRAMUSCULAR	NDA	22 sections
ROBAXIN	HUMAN PRESCRIPTION DRUG LABEL	1	0641-6217	INJECTION	100 mg	INTRAMUSCULAR	NDA	22 sections
Methocarbamol	HUMAN PRESCRIPTION DRUG LABEL	1	0904-7057	TABLET	500 mg	ORAL	ANDA	22 sections
Methocarbamol	HUMAN PRESCRIPTION DRUG LABEL	1	0904-7057	TABLET	500 mg	ORAL	ANDA	22 sections
Methocarbamol	HUMAN PRESCRIPTION DRUG LABEL	1	0904-7058	TABLET	750 mg	ORAL	ANDA	22 sections
Methocarbamol	HUMAN PRESCRIPTION DRUG LABEL	1	0904-7058	TABLET	750 mg	ORAL	ANDA	22 sections
Methocarbamol	HUMAN PRESCRIPTION DRUG LABEL	1	10135-664	TABLET, FILM COATED	500 mg	ORAL	ANDA	19 sections
Methocarbamol	HUMAN PRESCRIPTION DRUG LABEL	1	10135-665	TABLET, FILM COATED	750 mg	ORAL	ANDA	19 sections
Methocarbamol Tablets, USP, 500 mg	HUMAN PRESCRIPTION DRUG LABEL	1	10135-722	TABLET, FILM COATED	500 mg	ORAL	ANDA	20 sections
Methocarbamol Tablets, USP, 750 mg	HUMAN PRESCRIPTION DRUG LABEL	1	10135-723	TABLET, FILM COATED	750 mg	ORAL	ANDA	20 sections
Methocarbamol	HUMAN PRESCRIPTION DRUG LABEL	1	10544-259	TABLET	750 mg	ORAL	ANDA	21 sections
Methocarbamol	HUMAN PRESCRIPTION DRUG LABEL	1	10544-464	TABLET	750 mg	ORAL	ANDA	22 sections
Methocarbamol	HUMAN PRESCRIPTION DRUG LABEL	1	10544-622	TABLET	750 mg	ORAL	ANDA	19 sections
Methocarbamol	HUMAN PRESCRIPTION DRUG LABEL	1	10544-773	TABLET	500 mg	ORAL	ANDA	22 sections
Methocarbamol	HUMAN PRESCRIPTION DRUG LABEL	1	10544-956	TABLET	750 mg	ORAL	ANDA	23 sections
METHOCARBAMOL	HUMAN PRESCRIPTION DRUG LABEL	1	16590-147	TABLET	500 mg	ORAL	ANDA	21 sections
METHOCARBAMOL	HUMAN PRESCRIPTION DRUG LABEL	1	16590-148	TABLET	750 mg	ORAL	ANDA	21 sections
ROBAXIN	HUMAN PRESCRIPTION DRUG LABEL	1	16590-981	TABLET, FILM COATED	750 mg	ORAL	NDA	11 sections
METHOCARBAMOL	HUMAN PRESCRIPTION DRUG LABEL	1	17511-505	TABLET, FILM COATED	500 mg	ORAL	ANDA	20 sections
METHOCARBAMOL	HUMAN PRESCRIPTION DRUG LABEL	1	17511-506	TABLET, FILM COATED	750 mg	ORAL	ANDA	20 sections
Methocarbamol	HUMAN PRESCRIPTION DRUG LABEL	1	21695-078	TABLET	500 mg	ORAL	ANDA	21 sections
Methocarbamol	HUMAN PRESCRIPTION DRUG LABEL	1	21695-079	TABLET	750 mg	ORAL	ANDA	21 sections
Methocarbamol	HUMAN PRESCRIPTION DRUG LABEL	1	25021-675	INJECTION, SOLUTION	100 mg	INTRAVENOUS	ANDA	23 sections
Methocarbamol	HUMAN PRESCRIPTION DRUG LABEL	1	31722-533	TABLET	500 mg	ORAL	ANDA	19 sections